Education
About Us
Working with TipRanks
Follow Us
Syndax Pharmaceuticals Inc (SNDX)
NASDAQ:SNDX
Earnings Data
Report Date
May 11, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.55Last Year’s EPS
-0.98Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful scientific progress: two successful launches, accelerating quarter-over-quarter revenue growth (Revuforj +38% QoQ; Niktimvo +22% QoQ), solid real-world evidence, a healthy year-end cash balance ($394M) and multiple near- and mid-term clinical catalysts (frontline pivotal trials and an IPF readout). Offsetting factors include a high 2026 expense run-rate (~$400M), still-short average treatment duration in year one for Revuforj (4–6 months), incomplete post-transplant maintenance uptake (~40%–45%) and the risk that pending clinical readouts or competitive dynamics could temper expectations. On balance, highlights and growth drivers substantially outweigh near-term risks, but upcoming readouts and execution on duration/maintenance adoption and expense control are critical.Company Guidance
Multiple Approvals and Successful Launches
Syndax launched 2 first- and best-in-class medicines in 2025 and achieved its third FDA approval within ~1 year, demonstrating strong commercial and R&D execution.
Revuforj: Robust Revenue and Quarterly Acceleration
Revuforj generated $124.8M in net revenue in 2025; Q4 Revuforj net revenue was $44.2M, up 38% quarter-over-quarter, with total prescriptions up ~35% QoQ and new patient starts up ~20% in Q4.
Revuforj Market Penetration and Label Expansion (NPM1)
Approximately 1,050 patients treated commercially since launch; approaching ~50% penetration of the KMT2A incident population in year one. NPM1 label expansion triples the annual addressable population to ~6,500 patients and formulary coverage in NPM1 reached ~97% of lives within 4 months of approval; NPM1 represented roughly 30% of new starts in Q4 and management expects this to grow materially.
Niktimvo: Strong Launch Performance and Contribution
Niktimvo reported $56M in Q4 net revenue (+22% QoQ) and ~$151.6M in 2025 net revenue (first 11 months). Syndax recorded $42.4M in collaboration revenue from Niktimvo in 2025. To date ~13,500 infusions have been administered to >1,400 patients, with persistency ~60%–70% at month 10 and ~90% of U.S. bone marrow transplant centers having prescribed the drug.
Company-Level Financials and Cash Position
Total Syndax revenue in 2025 was $172.4M. Cash, cash equivalents and marketable securities were $394M at year-end 2025. Management expects to reach profitability without additional capital.
Pipeline Advancement and Clear Clinical Catalysts
Enrollment underway in pivotal frontline trials for revumenib (EVOLVE-2, REVEAL, RAVEN); MAXPIRe (axatilimab in IPF) completed enrollment (~135 patients) with topline data expected Q4 2026; Phase III axatilimab chronic GVHD trial (steroids combo) topline expected early 2028 and a Phase II (ruxolitinib combo) early 2027.
Real-World Evidence and Investigator Data Supporting Efficacy
Real-world evidence: Moffitt reported ORR ~77% and MRD negativity ~75% in relapsed/refractory patients treated primarily with revumenib combination regimens; investigator-maintenance and post-transplant data (MD Anderson, City of Hope) reported favorable tolerability and encouraging outcomes.
Expense Guidance and Stability
Management guided 2026 R&D + SG&A of approximately $400M (excluding ~$50M estimated noncash stock compensation) and expects expenses to be relatively flat quarter-to-quarter, indicating predictable investment levels into commercialization and development.
SNDX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SNDX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $20.67 | $21.71 | +5.03% |
Nov 03, 2025 | $13.76 | $15.35 | +11.56% |
Aug 04, 2025 | $10.38 | $12.57 | +21.10% |
May 05, 2025 | $13.57 | $10.64 | -21.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Syndax Pharmaceuticals Inc (SNDX) report earnings?
Syndax Pharmaceuticals Inc (SNDX) is schdueled to report earning on May 11, 2026, After Close (Confirmed).
What is Syndax Pharmaceuticals Inc (SNDX) earnings time?
Syndax Pharmaceuticals Inc (SNDX) earnings time is at May 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SNDX EPS forecast?
SNDX EPS forecast for the fiscal quarter 2026 (Q1) is -0.55.